Delayed Antibiotic Therapy in Non-severe Ventilator Acquired Pneumonia (VAP) (DELAVAP)
Aggressive Versus Restrictive Initiation of Antimicrobial Treatment in Critically Ill Patients With Suspected Ventilator Acquired Pneumonia Without Severity : a Before and After Observational Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Maelle Martin, MD
- Phone Number: 02 44 76 80 55
- Email: maelle.martin@chu-nantes.fr
Study Locations
-
-
-
Nantes, France, 44000
- Recruiting
- University Nantes Hospital
-
Contact:
- Maelle Martin, MD
- Phone Number: 02 44 76 80 55
- Email: maelle.martin@chu-nantes.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Under mechanical ventilation from more than 48 hours
- Suspected for a ventilator acquired pneumonia, requiring a distal pulmonary bacterial sample
Exclusion Criteria:
- New or worsening shock requiring vasopressor
- New or worsening severe hypoxemia (PaO2/FiO2<150 in FiO2≥60% and peep 10)
- Patient under veno-veinous extracorporeal membrane oxygenation
- Neutropenia <1G/L or immunosuppressive treatment (including corticosteroids >6 months or >0.5mg/kg/j)
- Disease (endocarditis, spondylodyscitis, deep abcedation…) requiring prolonged antibiotic therapy
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Other
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Restrictive antibiotic strategy
|
Implementation of a restrictive (delayed) antibiotic strategy in Ventilator Acquired Pneumonia suspicion without severity symptoms.
|
|
Aggressive (immediate) antibiotic strategy
|
Implementation of an aggressive (immediate) antibiotic strategy in Ventilator Acquired Pneumonia suspicion without severity symptoms.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
antibiotic-free days
Time Frame: 28 days
|
antibiotic-free days until Day 28 of Intensive Care Units stay
|
28 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mechanical ventilation free days
Time Frame: 28 days
|
Mechanical ventilation free days during the first 28 days
|
28 days
|
|
Intensive care unit stay length
Time Frame: 28 days
|
28 days
|
|
|
Intensive care unit mortality
Time Frame: 28 days
|
28 days
|
|
|
Hospitality mortality
Time Frame: 28 days
|
28 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Disease Attributes
- Cross Infection
- Iatrogenic Disease
- Healthcare-Associated Pneumonia
- Pneumonia
- Pneumonia, Ventilator-Associated
- Anti-Infective Agents
- Antitubercular Agents
- Anti-Bacterial Agents
- Antibiotics, Antitubercular
Other Study ID Numbers
Other Study ID Numbers
- MR_DELAVAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.